vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Applied Digital Corp. (APLD). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $126.6M, roughly 2.0× Applied Digital Corp.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -11.4%, a 22.5% gap on every dollar of revenue. On growth, Applied Digital Corp. posted the faster year-over-year revenue change (98.2% vs 29.6%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-567.9M). Over the past eight quarters, Applied Digital Corp.'s revenue compounded faster (70.9% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
BAE Systems Digital Intelligence is an international defence and security technology firm owned by BAE Systems. They specialize in delivering digital solutions that enable rapid, data-driven decision-making. Their services, solutions and products span customers in Law Enforcement, National Security, Government Departments and Government Enterprises, Critical National Infrastructure, Telecommunications, the Military, and Space.
ANIP vs APLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $126.6M |
| Net Profit | $27.5M | $-14.4M |
| Gross Margin | — | 20.6% |
| Operating Margin | 14.1% | -24.5% |
| Net Margin | 11.1% | -11.4% |
| Revenue YoY | 29.6% | 98.2% |
| Net Profit YoY | 367.5% | 89.6% |
| EPS (diluted) | $1.14 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $126.6M | ||
| Q3 25 | $227.8M | $64.2M | ||
| Q2 25 | $211.4M | $-33.3M | ||
| Q1 25 | $197.1M | $52.9M | ||
| Q4 24 | $190.6M | $63.9M | ||
| Q3 24 | $148.3M | $60.7M | ||
| Q2 24 | $138.0M | $43.7M | ||
| Q1 24 | $137.4M | $43.3M |
| Q4 25 | $27.5M | $-14.4M | ||
| Q3 25 | $26.6M | $-16.9M | ||
| Q2 25 | $8.5M | $-52.5M | ||
| Q1 25 | $15.7M | $-35.6M | ||
| Q4 24 | $-10.3M | $-138.7M | ||
| Q3 24 | $-24.2M | $-4.2M | ||
| Q2 24 | $-2.3M | $-64.5M | ||
| Q1 24 | $18.2M | $-62.8M |
| Q4 25 | — | 20.6% | ||
| Q3 25 | — | 13.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 18.0% | ||
| Q3 24 | — | -0.6% | ||
| Q2 24 | — | -9.1% | ||
| Q1 24 | — | -8.6% |
| Q4 25 | 14.1% | -24.5% | ||
| Q3 25 | 15.9% | -34.7% | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 13.3% | -35.8% | ||
| Q4 24 | -2.3% | -29.1% | ||
| Q3 24 | -13.8% | 15.6% | ||
| Q2 24 | 3.7% | -68.4% | ||
| Q1 24 | 14.8% | -128.8% |
| Q4 25 | 11.1% | -11.4% | ||
| Q3 25 | 11.7% | -26.4% | ||
| Q2 25 | 4.0% | 157.8% | ||
| Q1 25 | 8.0% | -67.2% | ||
| Q4 24 | -5.4% | -217.2% | ||
| Q3 24 | -16.3% | -7.0% | ||
| Q2 24 | -1.7% | -147.5% | ||
| Q1 24 | 13.2% | -145.0% |
| Q4 25 | $1.14 | $-0.07 | ||
| Q3 25 | $1.13 | $-0.07 | ||
| Q2 25 | $0.36 | $-0.31 | ||
| Q1 25 | $0.69 | $-0.16 | ||
| Q4 24 | $-0.45 | $-0.66 | ||
| Q3 24 | $-1.27 | $-0.03 | ||
| Q2 24 | $-0.14 | $-0.57 | ||
| Q1 24 | $0.82 | $-0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $1.4B |
| Total Assets | $1.4B | $5.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $1.9B | ||
| Q3 25 | $262.6M | $73.9M | ||
| Q2 25 | $217.8M | $41.6M | ||
| Q1 25 | $149.8M | $68.7M | ||
| Q4 24 | $144.9M | $286.2M | ||
| Q3 24 | $145.0M | $58.2M | ||
| Q2 24 | $240.1M | $3.3M | ||
| Q1 24 | $228.6M | $4.4M |
| Q4 25 | $540.7M | $1.4B | ||
| Q3 25 | $505.8M | $1.0B | ||
| Q2 25 | $436.8M | $497.7M | ||
| Q1 25 | $418.6M | $454.6M | ||
| Q4 24 | $403.7M | $434.6M | ||
| Q3 24 | $405.9M | $241.8M | ||
| Q2 24 | $455.8M | $124.8M | ||
| Q1 24 | $452.0M | $118.5M |
| Q4 25 | $1.4B | $5.2B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.3B | $1.9B | ||
| Q1 25 | $1.3B | $1.7B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.3B | $937.7M | ||
| Q2 24 | $920.8M | $762.9M | ||
| Q1 24 | $914.5M | $643.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-15.8M |
| Free Cash FlowOCF − Capex | $29.1M | $-567.9M |
| FCF MarginFCF / Revenue | 11.8% | -448.6% |
| Capex IntensityCapex / Revenue | 0.5% | 436.1% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-15.8M | ||
| Q3 25 | $44.1M | $-82.0M | ||
| Q2 25 | $75.8M | $6.9M | ||
| Q1 25 | $35.0M | $5.9M | ||
| Q4 24 | $15.9M | $-52.3M | ||
| Q3 24 | $12.5M | $-75.9M | ||
| Q2 24 | $17.4M | $-34.1M | ||
| Q1 24 | $18.3M | $38.8M |
| Q4 25 | $29.1M | $-567.9M | ||
| Q3 25 | $38.0M | $-331.4M | ||
| Q2 25 | $71.8M | $-191.4M | ||
| Q1 25 | $32.5M | $-251.6M | ||
| Q4 24 | $13.5M | $-223.3M | ||
| Q3 24 | $7.7M | $-130.7M | ||
| Q2 24 | $13.0M | $-88.9M | ||
| Q1 24 | $13.7M | $-2.3M |
| Q4 25 | 11.8% | -448.6% | ||
| Q3 25 | 16.7% | -516.1% | ||
| Q2 25 | 34.0% | 574.8% | ||
| Q1 25 | 16.5% | -475.4% | ||
| Q4 24 | 7.1% | -349.6% | ||
| Q3 24 | 5.2% | -215.3% | ||
| Q2 24 | 9.4% | -203.5% | ||
| Q1 24 | 10.0% | -5.4% |
| Q4 25 | 0.5% | 436.1% | ||
| Q3 25 | 2.7% | 388.4% | ||
| Q2 25 | 1.9% | -595.4% | ||
| Q1 25 | 1.3% | 486.6% | ||
| Q4 24 | 1.3% | 267.8% | ||
| Q3 24 | 3.2% | 90.3% | ||
| Q2 24 | 3.2% | 125.4% | ||
| Q1 24 | 3.3% | 95.0% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
APLD
| HPC Hosting Business | $85.0M | 67% |
| Data Center Hosting Business | $41.6M | 33% |
